Title |
Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans
|
---|---|
Published in |
Frontiers in Physiology, November 2015
|
DOI | 10.3389/fphys.2015.00342 |
Pubmed ID | |
Authors |
Martin Adiels, Adil Mardinoglu, Marja-Riitta Taskinen, Jan Borén |
Abstract |
To develop novel strategies for prevention and treatment of dyslipidemia, it is essential to understand the pathophysiology of dyslipoproteinemia in humans. Lipoprotein metabolism is a complex system in which abnormal concentrations of various lipoprotein particles can result from alterations in their rates of production, conversion, and/or catabolism. Traditional methods that measure plasma lipoprotein concentrations only provide static estimates of lipoprotein metabolism and hence limited mechanistic information. By contrast, the use of tracers labeled with stable isotopes and mathematical modeling, provides us with a powerful tool for probing lipid and lipoprotein kinetics in vivo and furthering our understanding of the pathogenesis of dyslipoproteinemia. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 33% |
Switzerland | 1 | 33% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Finland | 1 | 3% |
Unknown | 30 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 7 | 23% |
Student > Ph. D. Student | 6 | 19% |
Student > Master | 4 | 13% |
Student > Bachelor | 3 | 10% |
Student > Doctoral Student | 2 | 6% |
Other | 4 | 13% |
Unknown | 5 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 10 | 32% |
Agricultural and Biological Sciences | 5 | 16% |
Medicine and Dentistry | 4 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
Computer Science | 1 | 3% |
Other | 3 | 10% |
Unknown | 7 | 23% |